120 related articles for article (PubMed ID: 28067889)
1. BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
Fair C; Shanley R; Rogosheske J; Lazaryan A; McClune B; Brunstein CG; Bachanova V
Bone Marrow Transplant; 2017 Mar; 52(3):491-493. PubMed ID: 28067889
[No Abstract] [Full Text] [Related]
2. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
3. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
[TBL] [Abstract][Full Text] [Related]
4. Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Farnault L; Venton G; Pourroy B; Jourde-Chiche N; Ivanov V; Arcani R; Roche P; Mercier C; Colle J; Fanciullino R; Costello RT
Bone Marrow Transplant; 2019 Jul; 54(7):1173-1175. PubMed ID: 30718799
[No Abstract] [Full Text] [Related]
5. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
[TBL] [Abstract][Full Text] [Related]
6. [What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].
Ernst S; Bühlmann M; Stucki A; Bükki J; Stanga Z
Praxis (Bern 1994); 2007 Jan; 96(4):99-100. PubMed ID: 17294584
[No Abstract] [Full Text] [Related]
7. [Bacteremia due to Capnocytophaga spp.: two cases].
García J; Lizasoain M; Lahuerta JJ; Sanz F
Enferm Infecc Microbiol Clin; 2003 Mar; 21(3):168-9. PubMed ID: 12586027
[No Abstract] [Full Text] [Related]
8. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
[TBL] [Abstract][Full Text] [Related]
11. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
12. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
13. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
14. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
15. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Samaras P; Buset EM; Siciliano RD; Haile SR; Petrausch U; Mischo A; Honegger H; Pestalozzi BC; Schanz U; Stussi G; Stahel RA; Knuth A; Renner C; Stenner-Liewen F
Oncology; 2010; 79(1-2):93-7. PubMed ID: 21079406
[TBL] [Abstract][Full Text] [Related]
16. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
[TBL] [Abstract][Full Text] [Related]
17. Trial of amifostine in autologous stem cell transplant.
Sastry P; Bhagwat R; Biswas G; Khadwal A; Narayanan P; Bakshi A; Parikh P
Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
[No Abstract] [Full Text] [Related]
18. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Reid RM; Baran A; Friedberg JW; Phillips GL; Liesveld JL; Becker MW; Wedow L; Barr PM; Milner LA
Cancer Med; 2016 Nov; 5(11):3059-3067. PubMed ID: 27699999
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Vose JM; Bierman PJ; Loberiza FR; Enke C; Hankins J; Bociek RG; Chan WC; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2013 Jan; 19(1):123-8. PubMed ID: 22940055
[TBL] [Abstract][Full Text] [Related]
20. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Bou Akl I; Matar M; Khalil PB; Massoud R; Ghaoui N; Karout L; Zahreddine A; Bazarbachi A; El-Cheikh J
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):371-376.e1. PubMed ID: 32151585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
